Amino acid
    Free referrals to caregivers practicing this approach
         
Amino acid        
Amino acid        
Amino acid        
         
 
 
Home Page
Continuing Medical Ed
Peer-reviewed writings
website bibliography
Locate a caregiver
 
MEET THE RESEARCHERS who invented OCT2 transporter analysis
 
Neurotransmitter intro
Protocols
Side effects home page
Multiple disease treatment
Drug induced NT depletion
Amino acid depletion
NT Depletion Library
Nutrient urban legends
Testimonials
 
The diseases
Addiction
ADHD
Adrenal fatigue
Aging
Anxiety / Panic attacks
Alzheimer's
Attention deficit
Benign essential tremor
Bipolar depression
Cognitive impairment
Concussion
Chronic pain
Crohn's disease
Depression
Depression, refractory
Dementia
Fibromyalgia
GABA management
Irritable bowel disease
Insomnia
Intellectual disability
Interstitial cystitis
Migraine headaches
Mood disorder NOS
Obesity
OCD
Oppositional defiant disorder
Parkinson's disease
PMDD
PTSD
Restless leg syndrome
Tourette's syndrome
Trichotillomania
Ulcerative colitis
 
Study: Stiff man syndrome
Study: Crohn's
Medical education website
Sitemap  
5-HTP forum
Dr Stein-proloshot website
Alvin Stein, MD
Contact us

For more medical education information click here

 

Amino acid

Protocols

 
The improper functioning of the OCT2 monoamine transporters is responsible for the complex of symptoms which are categorized as diseases discussed on this website. Administration of drugs can further interfere with normal OCT2 transporter function. OCT2 transporter analysis is used to guide the administration of nutrients needed to compensate for the synaptic and post-synaptic electrical dysfunction that is causing these symptoms. Drugs treat symptoms, this approach treats the cause. The approach is based on the research of Marty Hinz, MD
 
 

Contact Alvin Stein, MD

 
website PERSPECTIVE: When symptoms relating to serotonin, dopamine, norepinephrine and/or epinephrine are present, the body configures the OCT2 transporters to compensate for the electrical problems causing the abnormalities, but these transporters fall short and fail to get the job done. This approach determines and then meets the nutritional needs of the OCT2 transporters leading to establishment of balanced synaptic neurotransmitter levels, optimal post-synaptic electrical function, and relief of symptoms. Alvin Stein, MD
 
Figure 1

 
 
A physician's comments on these protocols
 
Protocol overview

 
 

Full text reference cited immediately above

 
 

Amino acid

PERSPECTIVE: The amino acid starting point for all adult diseases (except Parkinson's disease and Restless leg syndrome) is the same since we are not treating the individual diseases. The patients have a relative nutritional deficiency that results in the presence of the disease symptoms and fails to allow an adequate supply of electrical activity in the brain.
 
 

Full text reference cited immediately above

 
 
 The OCT2 transporter are responsible for correcting the functions of the system. In the absence of adequate amino acid precursors of the centrally acting monoamines (serotonin, dopamine, norepinephrine and/or epinephrine), symptoms are present. The OCT2 transporter cannot function properly under these conditions.
 
 

Full texts reference for the quote immediately above

 
 
PROTOCOLS

Do not stop any prescription drug which the patient may be taking at the start of treatment since this may cause an exacerbation or relapse of symptoms.
Drug dosing values should only be decreased or stopped when:
- Symptoms are fully under control for 2 to 8 weeks
 

OR

 
- A drug side effect develops
 
 
 

Amino acid

Protocols

 
 
General Adult Amino Acid Protocol
(may be used with all adult diseases)
START OF TREATMENT:
Dr. Hinz developed nutritional formulas which for I will simply refer to as "NR", "DV", "DVE", "DVM", "RE", "TR", and "CR".
  4 pills "NR" in the AM and 4 PM
  2 pills "CR" 3 times a day (first dose at noon)
SEVEN DAYS LATER:
  Obtain a urine sample and submit it for serotonin and dopamine OCT2 transporter analysis if symptoms are still present.
NOTE: Continue adjusting amino acid dosing values as test results indicate and repeat testing until symptoms are under control.
         
 

Pediatric Amino Acid Protocol  (16 years and less)

START OF TREATMENT:
  2 pills "NR" in the AM and 4 PM
  1 pill "CR" times a day with first dose at noon
SEVEN DAYS LATER:
  Obtain a urine sample and submit it for serotonin and dopamine OCT2 transporter analysis if symptoms are still present.
NOTE: Continue adjusting amino acid dosing values as test results indicate and repeat testing until symptoms are under control.
         
 
L-dopa Amino Acid Protocol
(Parkinson's disease and Restless leg syndrome)
 
START OF TREATMENT:
  4 pills "DV" in the AM and 4 PM
  2 pills "CR" 3 times a day (first dose at noon)
ONE WEEK AFTER STARTING (7 DAYS)
  Continue pills started previous week then: then:
  Start 2 pills "DVM" 3 times a day
TWO WEEKS AFTER STARTING
  Obtain a urine sample and submit it for serotonin and dopamine OCT2 transporter analysis if symptoms are still present
NOTE: All Parkinson's disease patients must be made to understand that it can take 4 to 6 months or more for symptoms to stabilize provided weekly visits are arranged. If visits are every 2 weeks, it can take 8 to 12 months for symptoms to stabilize. Continue adjusting amino acid dosing values as test results indicate and repeat testing until symptoms are under control
         
 

Weight Loss (Obesity)

START OF TREATMENT:
Level 1 4 pills "NR" in the AM and 4 PM
  2 pills "CR" 3 times a day (first dose at noon)
ONE WEEK AFTER STARTING (7 DAYS)
If the patient has significant hunger at the end of seven days increase to:
Level 2 4 pills "NR" in the AM and noon with 4 "RE" at 4 PM
  2 pills "CR" 3 times a day (first dose at noon)
TWO WEEKS AFTER STARTING
If the patient has significant hunger at the end of 14 days, increase to
Level 3 4 pills "NR" in the AM and noon with 4 "RE" at 4 PM and 7 PM
  2 pills "CR" 3 times a day (first dose at noon)
THREE WEEKS AFTER STARTING
If the patient has significant hunger at the end of 21 days:
  Obtain a urine sample and submit it for serotonin and dopamine OCT2 transporter analysis if symptoms are still present.
NOTE: Weight loss medicine is very challenging to practice; it is recommended that proper training and orientation be obtained prior to applying this protocol to patients.
 
 

TREATMENT PEARLS: Each time there is a start or change in the amino acid dosing values it takes 3 to 5 days for serotonin and dopamine to stabilize (reach equilibrium). The patients need to be seen for follow up 7 days after a dosing change since outcomes like paradoxical reactions, etc. are unpredictable (NOT 1 to 3 months after a start or dosing value change). When seen in clinic, the proper question to ask the patient is, “How were your symptoms yesterday?” Note that yesterday should be day six since the amino acid dosing was changed. If symptoms were under control “yesterday,” continue the amino acid dosing value, do not obtain a urine sample, and follow up in one week. If symptoms were present “yesterday,” continue the amino acid dosing value and submit a urine sample for serotonin and dopamine OCT2 transporter analysis.

 
Reference cited immediately above
 
 
 
 

Basis Renal-Monoamine Science

    Serotonin and catecholamines do not cross the blood-brain barrier. Reference

    Urinary serotonin and dopamine are not simply filtered by the kidneys then excreted in the urine. Reference

    In patients not suffering from a hyperexcreting tumor, the serotonin and dopamine found in the urine were synthesized by the kidneys. Reference

    Urinary serotonin and catecholamines have not been in the central or peripheral systems. Reference

    There is no direct relationship between amino acid dosing and urinary serotonin and dopamine levels. Reference

    Simply determining if the serotonin and dopamine levels in the urine are high or low is of no value if phase determination is not performed simultaneously in the competitive inhibition state. Reference

    Serotonin and dopamine levels found in the urine are a function of the Organic Cation Transporters (OCT2 transporter) in the kidneys.

    The OCT2 transporters of the liver, brain, and kidneys are functionally "identical and homologous." Reference

    Urinary assays in the competitive inhibition state represent serotonin and dopamine not transported by the OCT2 transporter out of the proximal convoluted renal tubule cells into the system. Reference

 
 
 

If you want to read a big controversial blog on this approach here it is

 

 
 
 

Contact Alvin Stein, MD

 
 
 

The OCT2 transporter functional status optimization developed by Marty Hinz, MD is the only way to properly manage the following amino acid and/or neurotransmitter depletion problems (depletion may induce or exacerbate disease symptoms).

References: #1, #2, #3, #4, #5

 

Full text reference cited immediately above
 
 

Spring 2014 six hours AMA category 1 continuing medical education

 
 
Amino acid
Link
amino acid CME
amino acid wiki
amino acid NIH
amino acid U of AZ
 
Amino acid
medical amino acid research amino acid care
 

Amino Acid Protocols

Protocols
Treatment pearls
Clinic appointments
On-Off amino acid response
 
THE SCIENCE
HPA Methylation Epinephrine
Methylation
Adrenaline
Mitochondrial optimization
 
The myths baseline testing
Overview
What are transporters?
OCT2 transporter
5-HTP
Neurotoxins

.

Nutritional deficiency
Neurotransmission
Competitive Inhibition
Endogenous V. Competitive
OCT2 transporter optimization
 
Intro to OCT2 transporter lab testing
Lab interpretation part 1
Lab interpretation part 2
Lab interpretation part 3
 
amino acid
steinrockor
amino acid